Bristol-Myers Squibb (BMY.US) rises in pre-market trading! Two experimental drugs report positive results in Phase 3 clinical trials, diversifying and accelerating the pipeline

According to Zhitong Finance APP, Bristol-Myers Squibb (BMY.US) has achieved success in phase III clinical trials for two experimental drugs used to treat a rare endocrine cancer and a deadly lung disease, giving a boost to the company's new product pipeline. Driven by this news, as of press time, Bristol-Myers Squibb's shares were up nearly 4% in U.S. pre-market trading on Monday.

Bristol-Myers Squibb stated that the phase III ALPFT-IPF trial of the LPA1 antagonist Admilparant for the treatment of idiopathic pulmonary fibrosis (IPF) reached the primary endpoint for forced vital capacity (FVC). This trial is the third and final stage of clinical trials required before a new drug can be approved. Idiopathic pulmonary fibrosis is a chronic disease that causes scarring in the lungs, making it difficult for oxygen to enter the bloodstream. It is reported that patients with idiopathic pulmonary fibrosis showed significant improvements in respiratory health after taking a lower-dose version of Admilparant.

Meanwhile, Bristol-Myers Squibb announced that its SSTR2-targeted radiotherapeutic RYZ101 achieved the primary endpoint of progression-free survival (PFS) in a mid-stage analysis of the ACTION-1 phase III trial for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NET). This phase III trial targets patients receiving Lu-177-based therapy. Gastroenteropancreatic neuroendocrine tumors are a rare cancer originating from endocrine cells in the gastrointestinal tract or pancreas. The analysis found that RYZ101 could significantly slow disease progression.

Bristol-Myers Squibb is diversifying its pipeline as a strategic layout to cope with the impact of the expiry of patents on multiple key products. The company aims to launch more than 10 new drugs by 2030 and to build a diversified product portfolio covering multiple therapeutic areas.

At the beginning of the year, Bristol-Myers Squibb emphasized six pipeline projects with multibillion-dollar sales potential, including the antipsychotic Cobenfy (cenobamate + trospium chloride), the anticoagulant Milvexian, the pulmonary fibrosis drug Admilparant, the PD-L1/VEGF-A bispecific antibody Pumitamig, as well as two molecular glue drugs Iberdomide and Mezigdomide. These projects span neuroscience, cardiovascular, immunology, oncology, and other fields.

Bristol-Myers Squibb CEO Chris Boerner revealed that the company completed $30 billion in deals over the past two years, including five deals made in 2025, and will continue to drive better growth through strategic transactions in the future.